key: cord-0798762-nybhaf7n
authors: Ferraris, Augusto; Angriman, Federico; Szmulewicz, Alejandro G
title: Antipsychotic use and psychiatric disorders in COVID-19
date: 2021-02-03
journal: Lancet Healthy Longev
DOI: 10.1016/s2666-7568(20)30063-5
sha: dcef2bb3656124444fd9b63f6de471492d43b700
doc_id: 798762
cord_uid: nybhaf7n

nan

Although we acknowledge the perils of disentangling causal path ways (ie, the estimation of total causal effects requires less stringent assumptions than the identification of direct and indirect effects), further understanding of the mechanisms underlying the association between psychiatric illness and COVID-19 remains warranted. As such, in addition to the potential mechanisms pointed out by the authors (eg, immune response, impairment mediated by the endocrine axis, and cytokine production dysregulation), the use of antipsychotic medications requires attention.

People who use antipsychotics are at increased risk of infection, including community-acquired pneumonia, 2 urinary tract infections, 3 and bloodstream infections. 4 Because patients in Yang and colleagues' study were mainly diagnosed with depression, substance misuse, and anxiety-conditions that are increasingly treated with antipsychotic agents-we believe that such risk might partly explain the observed association between psychiatric illness, COVID-19, and its severity. The findings of strong associations between psychotic disorders and risk of poor outcomes of COVID-19 might point to antipsychotics as potential culprits.

Thus, we believe the study by Yang and colleagues emphasises a clear need for further research evaluating the association between psychiatric disorders, antipsychotic use, the dysregulation of the immune response, and the occurrence of life-threatening infections. Future studies should assess the role of antipsychotic treatment in infection, to shed light on the underlying mechanisms of the effect of psychiatric disorders on SARS-CoV-2 infection. Comparison between different antipsychotic medi cations would be of special relevance given that the risk does not appear to be uniform across agents-ie, both clozapine and pure dopaminergic agents might carry a higher infection risk. 4, 5 We declare no competing interests. 

Pre-pandemic psychiatric disorders and risk of COVID-19: a UK Biobank chort analysis

Antipsychotic drug use and pneumonia: systematic review and meta-analysis

Association between urinary tract infections and antipsychotic drug use in older adults

Antipsychotic use and bloodstream infections among patients with chronic obstructive pulmonary disease: a cohort study

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study